Re: 'Efficacy and Safety of the New Oral Anticoagulants Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the Treatment and Secondary Prevention of Venous Thromboembolism: A Systematic Review and Meta-analysis of Phase III Trials'- Key Learning Points for Surgeons.
Nuffield Department of Surgical Sciences, Oxford, UK.
K V
KV
Hurst
Nuffield Department of Surgical Sciences, Oxford, UK.
R
R
Lee
Nuffield Department of Surgical Sciences, Oxford, UK.
I
I
Milosevic
Nuffield Department of Surgical Sciences, Oxford, UK. Electronic address: ashok.handa@nds.ox.ac.uk.
A
A
Handa
D000925:Anticoagulants / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D011720:Pyrazoles / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D011728:Pyridones / Q000627:therapeutic use*; D055502:Secondary Prevention; D013844:Thiazoles / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D054556:Venous Thromboembolism / Q000188:drug therapy*; D015091:beta-Alanine / Q000031:analogs & derivatives*
D000925:Anticoagulants; D001562:Benzimidazoles; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; D015091:beta-Alanine